Pictet-Biotech -R EUR

Reference Data

ISIN LU0255977539
Valor Number 2564946
Bloomberg Global ID BBG000Q7HBF6
Fund Name Pictet-Biotech -R EUR
Fund Provider Pictet Asset Management S.A. Genève, Switzerland
Phone: +41 58 323 10 24
www.assetmanagement.pictet
Fund Provider Pictet Asset Management S.A.
Representative in Switzerland Pictet Asset Management S.A.
Genève 73
Phone: +41 58 323 30 00
Distributor(s) Credit Suisse AG
Zürich
Phone: +41 44 333 11 11 UBS AG
Zürich
Phone: +41 44 234 11 11 Vontobel Fonds Services AG
Zürich
Phone: +41 58 283 74 77
Asset Class Equities
EFC Category Equity Health Care
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition The fund does not charge any issuing commission and/or fees (units are issued at the NAV)
Redemption Condition The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV)
Investment Strategy *** To increase the value of your investment while seeking to achieve a positive social impact. The Fund applies a sustainable strategy and invests at least two-thirds of its net assets in equities or similar securities issued by biopharmaceutical companies throughout the world. Companies supporting the health of people with high innovation capacity. Better therapies can deliver true value to patients and healthcare systems alike. These companies are tackling high unmet medical needs and reduce the pressures on healthcare budgets through the reduction of hospital admissions or symptom management. The Fund invests mainly in companies whose significant proportion of their activities are related to, but not limited to, new mechanisms of actions offering potential cures or management of diseases that were hard to treat before, technology platforms, research tools and services in the biotechnology value chain as well as the improvement of therapies or drugs.
Peculiarities

Fund Prices

Current Price * 729.68 EUR 23.12.2024
Previous Price * 728.55 EUR 20.12.2024
52 Week High * 829.73 EUR 11.11.2024
52 Week Low * 665.07 EUR 25.04.2024
NAV * 729.68 EUR 23.12.2024
Issue Price *
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 1,422,897,673
Unit/Share Assets *** 161,304,209
Trading Information SIX

Performance

YTD Performance +5.03% 29.12.2023
23.12.2024
YTD Performance (in CHF) +5.40% 29.12.2023
23.12.2024
1 month -6.83% 25.11.2024
23.12.2024
3 months -3.60% 23.09.2024
23.12.2024
6 months -1.37% 24.06.2024
23.12.2024
1 year +5.79% 27.12.2023
23.12.2024
2 years +12.13% 23.12.2022
23.12.2024
3 years +2.55% 23.12.2021
23.12.2024
5 years +13.15% 23.12.2019
23.12.2024

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI 0.1536
ADDI Date 23.12.2024

Top 10 Holdings ***

argenx SE ADR 5.67%
Insmed Inc 4.52%
Sarepta Therapeutics Inc 4.05%
Intra-Cellular Therapies Inc 4.01%
TG Therapeutics Inc 3.30%
Vaxcyte Inc Ordinary Shares 3.24%
Blueprint Medicines Corp 3.10%
Gilead Sciences Inc 3.01%
SpringWorks Therapeutics Inc Ordinary Shares 2.81%
Cytokinetics Inc 2.80%
Last data update 30.11.2024

Cost / Risk

TER *** 2.701%
TER date *** 31.05.2024
Performance Fee ***
PTR
Max. Management Fee *** 2.90%
Ongoing Charges *** 2.70%
SRRI ***
SRRI date *** 30.11.2024

ESG Fund Ratings

Low Carbon Designation ***
ESG Rating Overall ***
ESG Rating Corporate ***
ESG Rating Sovereign ***
% AuM H&S Controversies ***

Breakdowns

Countries ***

Stock Sectors ***

Bond Sectors ***

ESG Carbon Metrics

Avg Carbon Risk Score ***
Avg Carbon Risk Cat Avg ***
% AuM Covered Carbon ***
Avg Fossil Fuel Exposure ***
Fossil Fuel Cat Avg ***

ESG Strategy

Strategy Level 1 *** Sustainable Investment
Strategy Level 2 ***
Strategy Level 3 ***
Exclusions Level 1 ***
Exclusions Level 2 *** GMOs

* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)